The healthcare system is at a breaking point, with clinician shortages, aging doctors, and increasing burnout pushing the industry to its limits. Julie Yoo, General Partner at a16z introduces her 2025 Big Idea: Super Staffing—a transformative approach leveraging AI to augment clinical capacity. We discuss how AI-powered co-pilots and autonomous agents are reshaping healthcare workflows, reducing administrative burdens, and addressing the growing supply-demand mismatch. With insights into rapid technology adoption and innovative models like asynchronous care, this episode unpacks how AI can unlock the latent potential of the healthcare workforce and improve patient outcomes. Timecodes: 00:00: The Healthcare Workforce Crisis 00:28: Understanding the Supply-Demand Mismatch 01:10: The Extent of the Shortage 02:21: Structural and Regulatory Constraints 05:06: Impact on Patients 07:10: Technological Solutions and Super Staffing 09:38: Current AI Tools in Healthcare 14:57: Challenges and Future Prospects 18:13: The Future of Healthcare and AI Resources: Find Julie on X: https://x.com/julesyoo Check out all 50 Big Ideas: https://a16z.com/big-ideas-in-tech-2025/ Stay Updated: Let us know what you think: https://ratethispodcast.com/a16z Find a16z on Twitter: / a16z Find a16z on LinkedIn: / a16z Subscribe on your favorite podcast app: https://a16z.simplecast.com/ Follow our host: / stephsmithio Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.
In 2023, a wave of therapies hailed as miracle drugs — including GLP-1’s and curative cell and gene therapies — had a profound impact in patients’ lives. With 3.6 million prescription claims for GLP-1s in 2022, the question arises: Can innovators establish a sustainable approach to bring these groundbreaking drugs to market without causing financial strain or system breakdown? Julie Yoo, General Partner at Andreessen Horowitz, shares a compelling big idea for 2024: Democratizing “Miracle Drugs”. Timecodes: 00:00 - Big Ideas in Tech 2024 01:39 - Democratizing “Miracle Drugs” 02:35 - How a GPL-1 works and the potential impact of the drug 08:32 - Curative cell and gene therapies 11:21 - Drug costs and insurance systems 15:16 -The changes needed to enable drug access 17:36 - What solutions are being built? 20:48 - Policy, the FDA, and CMS Resources: View all 40+ big ideas: https://a16z.com/bigideas2024 Find Julie on X: https://twitter.com/julesyoo Stay Updated: Find a16z on Twitter: https://twitter.com/a16z Find a16z on LinkedIn: https://www.linkedin.com/company/a16z Subscribe on your favorite podcast app: https://a16z.simplecast.com/ Follow our host: https://twitter.com/stephsmithio Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.